دورية أكاديمية
Bedaquiline: a review of human pharmacokinetics and drug-drug interactions.
| العنوان: | Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. |
|---|---|
| المؤلفون: | van Heeswijk RP; Janssen Infectious Diseases BVBA, Beerse, Belgium rvheesw1@its.jnj.com., Dannemann B; Janssen Research & Development, LLC, Titusville, NJ, USA., Hoetelmans RM; Janssen Infectious Diseases BVBA, Beerse, Belgium. |
| المصدر: | The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2014 Sep; Vol. 69 (9), pp. 2310-8. Date of Electronic Publication: 2014 May 23. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 7513617 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1460-2091 (Electronic) Linking ISSN: 03057453 NLM ISO Abbreviation: J Antimicrob Chemother Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1997- : London : Oxford University Press Original Publication: London, New York, Academic Press. |
| مواضيع طبية MeSH: | Drug Interactions*, Antitubercular Agents/*pharmacokinetics , Antitubercular Agents/*pharmacology , Diarylquinolines/*pharmacokinetics , Diarylquinolines/*pharmacology, Antifungal Agents/pharmacology ; Antiviral Agents/pharmacology ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic ; Humans ; Tuberculosis, Multidrug-Resistant/drug therapy |
| مستخلص: | Bedaquiline has recently been approved for the treatment of pulmonary multidrug-resistant tuberculosis (TB) as part of combination therapy in adults. It is metabolized primarily by the cytochrome P450 isoenzyme 3A4 (CYP3A4) to a less-active N-monodesmethyl metabolite. Phase I and Phase II studies in healthy subjects and patients with drug-susceptible or multidrug-resistant TB have assessed the pharmacokinetics and drug-drug interaction profile of bedaquiline. Potential interactions have been assessed between bedaquiline and first- and second-line anti-TB drugs (rifampicin, rifapentine, isoniazid, pyrazinamide, ethambutol, kanamycin, ofloxacin and cycloserine), commonly used antiretroviral agents (lopinavir/ritonavir, nevirapine and efavirenz) and a potent CYP3A inhibitor (ketoconazole). This review summarizes the pharmacokinetic profile of bedaquiline as well as the results of the drug-drug interaction studies. (© The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.) |
| فهرسة مساهمة: | Keywords: CYP3A; HIV; clinical trials; tuberculosis |
| المشرفين على المادة: | 0 (Antifungal Agents) 0 (Antitubercular Agents) 0 (Antiviral Agents) 0 (Diarylquinolines) 78846I289Y (bedaquiline) |
| تواريخ الأحداث: | Date Created: 20140527 Date Completed: 20150410 Latest Revision: 20140813 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1093/jac/dku171 |
| PMID: | 24860154 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1460-2091 |
|---|---|
| DOI: | 10.1093/jac/dku171 |